SWOG S1011 trial questions the benefits of extended lymphadenectomy in bladder cancer

The SWOG S1011 randomized phase 3 trial found no significant improvement in disease-free or overall survival but a higher rate of grade 3-4 adverse events and an increased risk of death in the 90 days after surgery.

Empowering Asthma Care: Bedfont® Scientific Limited Provides Vital Support for FeNO Testing in Response to Updated NICE Asthma Guidelines

The latest NICE guidelines on asthma emphasize FeNO testing. Bedfont® provides resources and support for healthcare professionals implementing these changes.

November 29, 2024

South Park Takes on Wegovy; Decapitated Doc’s Killer Sentenced; Deadliest Superbugs

Note that some links may require registration or subscription. A new special of the TV show “South Park” will take on the rising use of

May 18, 2024

Rising incidence and mortality rate of hepatocellular carcinoma in the USA: A comprehensive analysis

Over the past two decades, there has been a significant increase in the incidence of primary liver cancer in the USA, with higher rates observed

February 21, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.